Skip to main content

Table 1 Table of preclinical genetically engineering murine models

From: Developing preclinical models of neuroblastoma: driving therapeutic testing

Mouse Model

Advantages

Limitations

References

TH-MYCN

Representative of high-risk NB, high rate of tumor incidence

Long time for tumor development, few metastasis, limited background strain

[34,35,36,37,38,39,40,41,42,43]

LSL-MYCN;Dbh-iCre

Better defined transgene insertion then TH-MYCN, high rate of incidence in multiple background strains

Few metastasis, Limited work with preclinical therapeutic testing

[44]

TH-MYCN/CASP8(KO)

Metastasis, high rate of tumor incidence

Altered ECM structure of primary tumor

[45]

TH-MYCN/Trp53(KI)

Inducible p53 loss

p53 mutation more frequently present in recurrences, survival in mice greatly reduced

[46]

ALK (F1174)

Consistent with NB phenotype

Only present in 10% of NB

[47, 48]

TH-MYCN/ALK(F1174)

High tumor incidence, faster tumor growth

Relevance is limited to < 10% patients

[48]

SV40 Tag

Consistent with NB phenotype, high tumor incidence rate, metastasis

All mice die by 28 weeks of age

[49,50,51]